Health Desk-- 28 July, 2018: Hundreds of people are set to their jobs as UK-based pharmaceuticals giant GlaxoSmithKline has announced to shut down its pharmaceutical unit in Bangladesh by the end of this year.
The closure might affect around 1,000 people the company employs at its factory at Fouzderhat in Chattogram.
The company on Thursday after a board meeting announced that it will close down the pharmaceutical operations in Bangladesh but the main consumer healthcare products will stay in the market.
Around 500 employees of GSK Bangladesh on Friday staged demonstrated in front of the factory in Fouzderhat protesting the decision.
GlaxoSmithKline, however, claimed that all the Bangladeshi employees will not be affected by the closure as some them will be shifted to consumer healthcare unit.
The consumer healthcare unit accounts for 70 percent of the company’s portfolio in Bangladesh. GlaxoSmithKline will continue to produce Horlicks, Sensodyne and Glaxose D in Bangladesh as this business unit has been profitable, representatives of the company told reporters at a briefing at Westin Dhaka in city’s Gulshan.
GSK Bangladesh’s chairman M Azizul Haque was also present at the briefing.